In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Y-Mabs Therapeutics Inc (YMAB). The company’s shares opened today at $22.68.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 3.8% and a 42.4% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Y-Mabs Therapeutics Inc with a $40 average price target, representing a 76.4% upside. In a report issued on July 2, H.C. Wainwright also reiterated a Buy rating on the stock with a $40 price target.
See today’s analyst top recommended stocks >>
Based on Y-Mabs Therapeutics Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $15.93 million. In comparison, last year the company had a GAAP net loss of $3.83 million.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company’s services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
